Pioneering neuro-metabolic therapies for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead programs on track for INDs this year, with clinical data in 2025 Additional pipeline programs in Alzheimer’s disease, epilepsy, and depression Pipeline Program […]
Location: United States
Total raised: $75M
Investors 2
| Date | Name | Website |
| - | Chugai Ven... | chugaivent... |
| 08.08.2024 | Newpath Ma... | newpath.pa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.08.2026 | Series A | $30M | Eli Lilly ... |
| 30.10.2024 | - | $45M | - |
Mentions in press and media 10
| Date | Title | Description |
| 17.08.2026 | Trajectory Raises $40M in Series A Funding at $300M Post-Money Valuation | Trajectory, a San Francisco, CA-based provider of an AI infrastructure and agent optimization platform, raised $40m in Series A funding at a $300m post-money valuation. The round was led by Sequoia Capital, with participation from NVIDIA an... |
| 17.08.2026 | Leal Therapeutics Raises $30M in Second Close of Series A Funding | Leal Therapeutics, a Worcester, MA-based provider of neuro-metabolic therapeutics for central nervous system disorders, raised $30M in the second close of its Series A funding. Backers included Eli Lilly and Company, OrbiMed, Newpath Partne... |
| 17.08.2026 | Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia | WORCESTER, Mass., Aug. 17, 2026 /PRNewswire/ -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced a second close of $30 million of its Series A... |
| 17.08.2026 | Leal Therapeutics Raises $30 Million Series A Extension With Lilly As Schizophrenia Trial Begins | Leal Therapeutics has raised a $30 million second close of its Series A financing and initiated a Phase 1b/2a clinical trial of LTX-001 in adults with schizophrenia. Eli Lilly joined the financing as a new investor. Existing investors OrbiM... |
| 17.08.2026 | Leal Therapeutics Inks $30 Million Series A Extension | WORCESTER, MA, Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company, announced a second close of $30 million of its Series A financing. >> Click here for more funding data on Leal Therapeutics >> To export... |
| 27.08.2025 | Leal Therapeutics Raises $30M in Series A Funding | Leal Therapeutics, a Worcester, MA-based biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), raised $30M in Series A funding. The round was led by SV Health Investors’ Dementi... |
| 30.10.2024 | Leal Therapeutics Announces $45 Million Financing | WORCESTER, MA, Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), announced a $45 million financing led by Newpath Partners. >> Click here f... |
| - | Leal Therapeutics | “Pioneering neuro-metabolic therapies for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead program... |
| - | Leal Therapeutics | “Pioneering precision medicines for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead programs on t... |
| - | Leal Therapeutics | - |